When the time comes, you'll be judged for your actions.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yes but it can take a few days.
Salee from the 22nd Dec 23 was reported on the 27th Dec 23 as an example
The submission on the 28th was an amendment to an existing submission.
The clock started on the 28th
No dilution...yet
Can you name 10?
parody?
1-A has been QUALIF
It will be interesting to see how much the doc sells at .15, I'm sure investors are queuing up that price.
Share price has doubled since - great call grasshopper.
weak again...you must try harder
It's an amendment to the prior filing and still hasn't been qualified so they can't sell any yet.
Go play elsewhere
Direct Interstitial Injection: An Approach to Optimizing Therapeutic Ratios for Safe and Effective Delivery of High-dose Radionuclide Therapy in Treating Solid Tumors (P446)
Mon, July 08
Gatlin C/D
Poster Session
Part of:
Poster Session 1
Info
Abstract Text:
The limiting constraint in all modes of radiation therapy is unwanted dose to non-target normal organs and tissues, which can cause severe side-effects. An ideal radionuclide therapy places 100% of the treatment dose uniformly within the clinical target volume without radionuclide out-migration from the tumor. Such treatment can be achieved by employing an optimum radionuclide and chemical form with carrier properties that facilitate injection, placement, and in-tumor retention. An optimized radiation dose achieves effective tumor destruction while preventing or minimizing normal tissue adverse reactions. Yttrium-90 emits no gamma rays and can be handled safely with negligible dose to workers, patients, and family members. Methods: Yttrium-90 was prepared as insoluble (yttrium phosphate) microparticles in a phosphate-buffered saline (PBS) solution mixed with a polymer composite (hydrogel) carrier for direct intra-tumoral injection. Privately owned cats, dogs, and horses presenting with soft-tissue sarcomas were treated at several veterinary clinics to demonstrate safety, best placement methods, and most effective treatment doses. Results: Upon injection using multiple parallel-needles, the carrier solution warmed and gelled in situ--forming a solid matrix that entrapped the Y-90 microparticles and prevented out-migration via blood circulation. Co-registered PET/CT imaging post-injection confirmed uniform placement in target tissues. Each subject exhibited an objective response to therapy; best results were associated with smaller tumors treated at higher doses (300 to 400 Gy). Treated animals experienced no radiation-related illness or adverse tissue reactions. Therapeutic ratios achieved ranged from 200:1 upwards to 10000:1. Complete tumor destruction was confirmed by histopathology. Conclusions: Some tumors represent poor candidates for surgical excision or cannot be treated using external beams for curative therapy. However, direct intra-tumoral injection of Y-90-microparticles in a polymer composite matrix provides a safe, efficient, high-dose therapy, with tumor cell killing associated with localized dose. Results of this research confirm the opportunity for multiple oncology applications in both human and veterinary patients.
Keywords:
radionuclide therapy cancer treatment yttrium-90
Session Topic:
MA5: Radiation Protection in Healthcare
Authors
Darrell R. Fisher, Ph.D.
Versant Medical Physics and Radiation Safety
Michael K. Korenko
They got me at lung cancer
It's definitely cheaper now than it was 5 years ago.
Flat out lie but nice try
..
IDE SUBMITTED
They don't, and I doubt Vivos will ever do it again as too many cry babies can't handle their emotions.
Totally agree, got to be a special kind of moron to need a daily update from team Vivos when they have already stated multiple times this is on track for Q2.
More lies
The company have already stated they are holding back the benzinga article for a tactical release
Alluded to here?
https://www.hopkinsmedicine.org/news/articles/2023/02/radiopharmaceutical-therapy-in-veterinary-patients
Krimins uses Y-90 hydrogel therapy to treat solid cutaneous malignant tumors. It can also be used inside the body following removal of an intra-cavitary malignant tumor to ensure all cancer cells are eradicated. The radioactive material is prepared and administered for each patient individually based on the type and location of the cancer and other factors. The Y-90 hydrogel is injected into the tumor at 5 millimeter spacings. Therapy is outpatient; animals can go home the same day as treatment. This newer radiopharmaceutical is not excreted, and it does not migrate or irradiate healthy tissue, Krimins noted. Post-treatment, owners are advised to limit prolonged direct contact between humans (especially children and pregnant women) and the treated tissue for several weeks following treatment to limit any potential exposure.
In her research, Krimins offers several case studies of patients treated for malignancy with Y-90 hydrogel. Francis, an 11-year-old Yorkshire terrier, had a cancerous high-grade soft tissue sarcoma removed, but still had signs of cancer around the edges of removed tissues (known as dirty margins). Since his treatment in January 2022, Francis is thriving and remains cancer-free. Oliver, a 12-year-old domestic shorthair cat, had a fibrosarcoma in a limb. The limb was amputated, but the fibrosarcoma grew back at the amputation site. Oliver was treated twice with Y-90 hydrogel, most recently in July 2022, with no tumor recurrence to date.
You said you held shares and expected the price to drop.
That is a flat out lie, if held shares and thought the price was going down you would have sold and bought back in at a lower price.
You and the word 'right' rarely get used in the same sentence.
Your calls for 4c while holding shares like a baggy still make me chuckle.
Ever spoke to him about Radiogel?
Can't see it myself, firstly they should be shouting from the roof tops as soon as they submit it, secondly the IDE submission is going to be a material event, so they need to report it within 3-4 days of submission.
Vivos have committed to the Q2 IDE submission for at least 2 months, I really can't believe they would have tasks stacked which meant they could only submit the IDE in the last few days of June.
It does generate revenue
Plenty of loss leading companies get sold, Isopet could easily be split away and sold for a handsome profit.
The abstract that will be presented by Dr K and D Fisher
Abstract Text:
The limiting constraint in all modes of radiation therapy is unwanted dose to non-target normal organs and tissues, which can cause severe side-effects. An ideal radionuclide therapy places 100% of the treatment dose uniformly within the clinical target volume without radionuclide out-migration from the tumor. Such treatment can be achieved by employing an optimum radionuclide and chemical form with carrier properties that facilitate injection, placement, and in-tumor retention. An optimized radiation dose achieves effective tumor destruction while preventing or minimizing normal tissue adverse reactions. Yttrium-90 emits no gamma rays and can be handled safely with negligible dose to workers, patients, and family members. Methods: Yttrium-90 was prepared as insoluble (yttrium phosphate) microparticles in a phosphate-buffered saline (PBS) solution mixed with a polymer composite (hydrogel) carrier for direct intra-tumoral injection. Privately owned cats, dogs, and horses presenting with soft-tissue sarcomas were treated at several veterinary clinics to demonstrate safety, best placement methods, and most effective treatment doses. Results: Upon injection using multiple parallel-needles, the carrier solution warmed and gelled in situ--forming a solid matrix that entrapped the Y-90 microparticles and prevented out-migration via blood circulation. Co-registered PET/CT imaging post-injection confirmed uniform placement in target tissues. Each subject exhibited an objective response to therapy; best results were associated with smaller tumors treated at higher doses (300 to 400 Gy). Treated animals experienced no radiation-related illness or adverse tissue reactions. Therapeutic ratios achieved ranged from 200:1 upwards to 10000:1. Complete tumor destruction was confirmed by histopathology. Conclusions: Some tumors represent poor candidates for surgical excision or cannot be treated using external beams for curative therapy. However, direct intra-tumoral injection of Y-90-microparticles in a polymer composite matrix provides a safe, efficient, high-dose therapy, with tumor cell killing associated with localized dose. Results of this research confirm the opportunity for multiple oncology applications in both human and veterinary patients.
An old article but Rebecca is with team Vivos so worth a read
https://www.hopkinsmedicine.org/news/articles/2023/02/radiopharmaceutical-therapy-in-veterinary-patients
You don't understand how offerings work. The company selling at the Ask? Lol
He doesn't know as much as bobb
If they did I want some of what they're are smoking.
Who's bobb?
Offering was for 50,000,000 shares
So far the following have been sold
15,000,000 +Â 16,132,000Â + 2,000,000Â +
11,000,000
Simply not true.
The reg A offering has been out for 3-4 month, why are you surprised they sold some of it?
That test has already been completed and passed.
Refute #1
BDD wouldn't have been granted without the Isopet data. The IDR wouldn't happen with Isopet data.
Let's see your response
C90..you must be thinking about another company.
The FDA granted a BDD for Radiogel and it's Y-90, safety has already been proven multiple times in animals..Infact the animal data was used and helped gain the BDD.